Navigation Links
Sciele Pharma Announces Successful Completion of New Sular,Formulation Clinical Trial Program

ATLANTA--(BUSINESS WIRE)--May 14, 2007--Sciele Pharma, Inc. (NASDAQ:SCRX) today announced the successful completion of the clinical trial program for its new Sular formulation. The study results showed that the new Sular formulation is bioequivalent to Sciele's currently marketed Sular. The new Sular formulation utilizes SkyePharma's (LSE:SKP) patented Geomatrix technology, which is designed to provide a lower dose of Sular for each of its current doses.

The data from this study will be combined with the results from the previous clinical trial in the Company's new Sular formulation supplemental New Drug Application (sNDA) filing. As previously announced, the Company confirms its expectation to file an sNDA with the U.S. Food and Drug Administration by end of the second quarter of 2007.

About Sciele Pharma, Inc.

Sciele Pharma, Inc. is a pharmaceutical company specializing in sales, marketing and development of branded prescription products focused on Cardiovascular/Diabetes and Women's Health. The Company's Cardiovascular/Diabetes products treat patients with high cholesterol, hypertension, high triglycerides, unstable angina and Type 2 diabetes, and its Women's Health products are designed to improve the health and well-being of women and mothers and their babies. Founded in 1992 and headquartered in Atlanta, Georgia, Sciele Pharma employs more than 800 people. The Company's success is based on placing the needs of patients first, improving health and quality of life, and implementing its business platform - an Entrepreneurial Spirit, Innovation, Speed of Execution, Simplicity, and Teamwork.

About SkyePharma PLC

Using its proprietary drug delivery technologies, SkyePharma develops new formulations of known molecules to provide a clinical advantage and life-cycle extension. The Company has ten approved products in the areas of oral, inhalation and topical delivery. The Company
'"/>




Page: 1 2 3 4

Related medicine technology :

1. SkyePharma and Sciele Pharma Announce Successful Completion of New Sular Formulation Clinical Trial Programme
2. Sygnis Pharma AG announces date for presentation of clinical results
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
(Date:10/22/2014)... -- Antigen Discovery Inc. (ADi), a privately held company ... receipt of a National Institutes of Health (NIH) Phase ... of Dental and Craniofacial Research (NIDCR). The one-year $225,000 ... Microarray Chip, which will contain every protein in all ... the development of safe and effective vaccines and therapies ...
(Date:10/22/2014)... 22, 2014  Paper Pak Industries, a manufacturer ... ® Body Guard Bio, a disposable, highly ... bacteria and virus while protecting service providers and ... features a rugged, external nylon shell, watertight zipper, ... leak-proof inner chamber that contains contaminated and potentially ...
(Date:10/22/2014)... , Oct. 22, 2014  With a vision ... health medications, a Global Pharmaceutical and Biotech manufacturer ... technology and turnkey solution to protect their animal ... http://photos.prnewswire.com/prnh/20141021/153438 Photo - ... was serialized and aggregated by the Xyntek and ...
Breaking Medicine Technology:Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2New, State-Of-The-Art Body Bag Minimizes The Spread Of Bacteria And Virus 2Xyntek and Antares Serialization Solution Protects Pets Too! 2
... Ventus Medical, Inc. a privately-held medical device company ... breathing, today announced that it has received CE ... (Photo:   http://photos.prnewswire.com/prnh/20110209/SF45785-b ) ... pleased to accomplish this important regulatory milestone. Receiving ...
... Cempra Pharmaceuticals today announced the appointment of David ... well as announcing an expansion of its clinical ... programs, solithromycin and TAKSTA ... significant anti-infective clinical development experience. Solithromycin ...
Cached Medicine Technology:Ventus Medical Receives CE Mark for Provent® Sleep Apnea Therapy 2Cempra Expands Clinical Management Team to Advance Leading Antibacterial Clinical Programs Solithromycin and TAKSTA™ 2Cempra Expands Clinical Management Team to Advance Leading Antibacterial Clinical Programs Solithromycin and TAKSTA™ 3
(Date:10/25/2014)... global HCIT outsourcing market is forecast to grow at ... 2018 from $35 billion in 2013. The health insurance ... the HCIT outsourcing market. These industries follow the HCIT ... reduce operational and maintenance costs, increase access to IT ... costs), share risk, and quickly implement new technologies. , ...
(Date:10/25/2014)... October 25, 2014 The ... which verifies IT-accessibility for disabled users by disabled ... logo to Mackin Educational Resources of Burnsville, ... management system and to the Minnesota Alliance for ... "Own Best Medicine" website. Both organizations ...
(Date:10/25/2014)... Mesothelioma researchers are reporting extended survival in ... after his combination drug therapy became too toxic. ... posted on the Surviving Mesothelioma website. , A ... Japan suggests that “maintenance therapy” with pemetrexed may be ... tolerate higher doses of cisplatin. , “Although the ...
(Date:10/25/2014)... 2014 (HealthDay News) -- Researchers who discovered antibiotics ... are cause for concern. The use of ... for human consumption contribute to the development of ... background information from the study. Each year ... 2 million people and kill about 23,000, according ...
(Date:10/22/2014)... At a time when the national ... athletes at all levels, the UPMC Sports Medicine ... discussion where two powerful messages are lost: Concussions can ... in full recoveries every day. , In striving to ... and research, UPMC and the Concussion Program are unveiling ...
Breaking Medicine News(10 mins):Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 2Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 3Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 4Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 2Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 3Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2Health News:Researchers Say Antibiotics in Fish a Health Concern 2Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 2Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 3Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 4
... price hikes in Nepal have irked student organizations who came ... The protestors blocked roads and stoned vehicles and burnt tyres ... commerce minister. The population of Nepal is furious with the ... costlier. ,The student wings of two of the leading ...
... only half of drug- or alcohol-addicted family members seek help ... to 82% of them. ,On interviewing about 902 U.S. ... Drug Addiction poll revealed that a member of their immediate ... ,The findings of the poll were that 51% said their ...
... been affected by bird flu killing thousands of ducks. Health ... infected ducks in from Vietnam. ,Ku Chanthan, a veterinary ... two people were admitted to the hospital on suspicion of ... around 1,300 ducks died from bird flu. Ku added that ...
... Nilambur in Malappuram district of Kerala is all set to ... be Class 4-literate//. Some of the credit would go to ... of that village in the age group 15-50 have not ... , The Kerala State Literacy Mission has organized the ...
... the government health officials, initial clinical trials show that ... ,"Forty-nine healthy people who received the injections ... the vaccine was safe," said Zhang Wei, head of ... Drug Administration (SFDA). ,"The recipients appeared immune ...
... that they say can detect the deadly anthrax in ... they are expensive// and time-consuming. Time is critical because ... ,Professor Peter Seeberger and his team at ... the anthrax surface molecule. They then attached this molecule ...
Cached Medicine News:Health News:Fuel Price Hike Triggers Violent Protests In Nepal 2Health News:Fuel Price Hike Triggers Violent Protests In Nepal 3Health News:Class 4 literacy to be attained by a Kerala village 2Health News:China’s AIDS vaccine-successfully finishes first phas 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: